A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
|
|
- Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302).
|
- Agreement to use contraception.
|
- Willing and able to comply with the study protocol and procedures.
|
- Further inclusion criteria apply.
|
|
|
- Participation in the extension study could expose the participant to an undue safety risk.
|
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
|
- Further exclusion criteria apply.
|
|
|
|
|
|
|
|
|
|
|
- Long-Term Extension (LTE)
|
|
|
|
|